Clinical Trials
109 trialsIsa Iber VD
Dana-Farber Cancer Institute
Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma
Medical College of Wisconsin
CONQUISTADOR
Universitätsklinikum Hamburg-Eppendorf
PrE1005
PrECOG, LLC.
In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms
Chinese PLA General Hospital
Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma
University of Iowa
Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS
NYU Langone Health
RISE
Gruppo Italiano Malattie EMatologiche dell'Adulto
RECLAIM
Medical College of Wisconsin
COGNITOX
University of Aarhus
Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis
Case Comprehensive Cancer Center
Study of Thiotepa Combination With Melphalan (TM Protocol) Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma：A Prospective Randomized Controlled Clinical Trial
First Affiliated Hospital Xi'an Jiaotong University
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
Institute of Hematology & Blood Diseases Hospital, China
BR101 in Patients With Relapsed/Refractory Multiple Myeloma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
Medical College of Wisconsin
CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms
The General Hospital of Western Theater Command
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
Affiliated Hospital to Academy of Military Medical Sciences
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
Washington University School of Medicine
Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers
Hackensack Meridian Health
Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
Vanderbilt-Ingram Cancer Center
BLOOD-dose
Rigshospitalet, Denmark
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Fred Hutchinson Cancer Center
CART-BCMA
Chulalongkorn University
CALySSEY
Baylor College of Medicine
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
University of Arkansas
DETERMINE
Cancer Research UK
CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms
Affiliated Hospital to Academy of Military Medical Sciences
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
CAREMM-007
Institute of Hematology & Blood Diseases Hospital, China
CM336-001
Institute of Hematology & Blood Diseases Hospital, China
Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Experimental, and Clinical Research
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
SL4903
Institute of Hematology & Blood Diseases Hospital, China
LB2505-0001
Institute of Hematology & Blood Diseases Hospital, China
COSTA
Duke University
SAPPHIRE-MM
University Hospital Heidelberg
A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
Tongji Hospital
Effects of Controlled Breathing on Cardiorespiratory Variables in Multiple Myeloma
Universidad Complutense de Madrid
KORMED-PA Stud
Seoul National University Bundang Hospital
IASO104
Institute of Hematology & Blood Diseases Hospital, China
Effects of Controlled Breathing Added to Therapeutic Exercise in Multiple Myeloma
Universidad Complutense de Madrid
Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma
Peking Union Medical College Hospital
Mezi-KD
Assistance Publique - Hôpitaux de Paris
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dana-Farber Cancer Institute
Isa-VRD in TIE HRMM
Peking Union Medical College Hospital
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
Peking University People's Hospital
MFM
Medical College of Wisconsin
IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.
Peking University First Hospital
ENTRAIDANT
Assistance Publique - Hôpitaux de Paris